You are here: Industry Insights > Market News > M&As this week: Sun Moral International (HK), Immuno Holding

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

M&As this week: Sun Moral International (HK), Immuno Holding

pharmaceutical-technologyMarch 27, 2017

Tag: immuno , M&As

Favorites

Sun Moral International (HK), a subsidiary of Chinese pharmaceutical company Sihuan Pharmaceutical Holdings Group, has acquired the entire equity interest in Ambest Pharmaceutical (China) Company.

"Immuno Holding’s subsidiary 1111267 B.C has reached an agreement to acquire Immunotec."

The target company is a manufacturer of large-volume injections and was acquired for a consideration of ¥1.1bn ($159.47m).

Immuno Holding’s subsidiary 1111267 B.C has reached an agreement to acquire Immunotec.

The purchase consideration for the acquisition is $0.485 a share.

Based in Canada, the target company develops, manufactures and sells nutritional products.

Previous:Cancer Research UK to support Precision Panc project for pancreatic cancer

Next:Biomedical Institute for Global Health Research and Technology (BIGHEART) at NUS and Holmusk Partner

New CRO Focused on Cannabis-based Drug Trials Launched

Biotech NewswireMay 23, 2024

Cannovation Clinical Research Partners takes a holistic approach to assist businesses throughout the entire product lifecycle, encompassing product development, commercialization, and launch phases.

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

M&As this week: Sun Moral International (HK), Immuno Holding | Pharmasources.com

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

M&As this week: Sun Moral International (HK), Immuno Holding

Related News

New CRO Focused on Cannabis-based Drug Trials Launched

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

You may like